Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Safety and Anti-Tumor Activity Study of Loncastuximab Tesirine and Ibrutinib in Diffuse Large B-Cell or Mantle Cell Lymphoma

Julien Depaus, Locke J. Bryan, MD, David Ungar, MD, Ilva Dautaj, Nina D. Wagner-Johnston, MD

Blood (2019) 134 (Supplement_1): 5309.

https://doi.org/10.1182/blood-2019-126913

Published: 2019

Journal Articles

Safety and Anti-Tumor Activity Study of Loncastuximab Tesirine and Durvalumab in Diffuse Large B-Cell, Mantle Cell, or Follicular Lymphoma

Craig H. Moskowitz, Mariana Bastos-Oreiro, MD PhD, David Ungar, MD, Ilva Dautaj, Matko Kalac, MD PhD

Blood (2019) 134 (Supplement_1): 2807.

https://doi.org/10.1182/blood-2019-128036

Published: 2019

Journal Articles

Results from Enestgoal: A Phase 2 Study of Treatment-Free Remission (TFR) in Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Switched from Imatinib to Nilotinib

Ellen K Ritchie, MD, Rosalind Catchatourian, MD, Rebecca B. Klisovic, MD, Javier Pinilla-Ibarz, MD PhD, Michael W. Deininger, MD PhD, Harry P. Erba, MD PhD, Jerald P. Radich, MD, Michael R. Savona, MD, Ilva Dautaj, MS, Das Purkayastha, Karen Habucky, PhD, Michael J. Mauro, MD

Blood (2017) 130 (Supplement 1): 2875.

https://doi.org/10.1182/blood.V130.Suppl_1.2875.2875

Published: 2017

Journal Articles

ENESTgoal Treatment-Free Remission Study: Updated Preliminary Results and Digital Polymerase Chain Reaction Analysis in Patients with Chronic Myeloid Leukemia in Chronic Phase Who Switched from Imatinib to Nilotinib

Ellen K. Ritchie, MD, Rose Catchatourian, MD, Rebecca B Klisovic, MD, Javier Pinilla-Ibarz, MD PhD, Michael W. Deininger, MD PhD, Harry P. Erba, MD PhD, Jerald P. Radich, Michael R. Savona, MD, Ilva Dautaj, MS, Johannes Wolff, MD, Michael J. Mauro, MD

Blood (2016) 128 (22): 3090.

https://doi.org/10.1182/blood.V128.22.3090.3090

Published: 2016

Journal Articles

ENESTnext Final Results: Deep Molecular Response (MR) with Nilotinib (NIL) in Patients (pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP)

Jesus G. Berdeja, MD, Michael Heinrich, Shaker Dakhil, MD FACP, Stuart L. Goldberg, MD, Martha Wadleigh, MD, Rosalind Catchatourian, MD, Philip Kuriakose, MD, Jorge E. Cortes, MD, Jerald P. Radich, David A. Rizzieri, MD, Gaetano Bonifacio, MD, Ilva Dautaj, Ghulam Warsi, PhD, Michael J. Mauro, MD

Blood (2015) 126 (23): 4048.

https://doi.org/10.1182/blood.V126.23.4048.4048

Published: 2015

Journal Articles

Rapid Achievement of MR 4.5 after Switching from Imatinib (IM) to Nilotinib (NIL) in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Preliminary Results from ENESTgoal

Ellen K. Ritchie, MD, Rosalind Catchatourian, MD, Rebecca B. Klisovic, MD, Michael W Deininger, MD PhD, Harry P. Erba, MD PhD, Jerald P. Radich, Michael R. Savona, MD, Ghulam Warsi, PhD, Carole S. Paley, Ilva Dautaj, Felice P. Lin, PharmD, Michael J. Mauro, MD

Blood (2015) 126 (23): 4050.

https://doi.org/10.1182/blood.V126.23.4050.4050

Published: 2015

NARROW

Safety and Anti-Tumor Activity Study of Loncastuximab Tesirine and Ibrutinib in Diffuse Large B-Cell or Mantle Cell Lymphoma

Safety and Anti-Tumor Activity Study of Loncastuximab Tesirine and Durvalumab in Diffuse Large B-Cell, Mantle Cell, or Follicular Lymphoma

Results from Enestgoal: A Phase 2 Study of Treatment-Free Remission (TFR) in Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Switched from Imatinib to Nilotinib

ENESTgoal Treatment-Free Remission Study: Updated Preliminary Results and Digital Polymerase Chain Reaction Analysis in Patients with Chronic Myeloid Leukemia in Chronic Phase Who Switched from Imatinib to Nilotinib

ENESTnext Final Results: Deep Molecular Response (MR) with Nilotinib (NIL) in Patients (pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP)

Rapid Achievement of MR 4.5 after Switching from Imatinib (IM) to Nilotinib (NIL) in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Preliminary Results from ENESTgoal

Email alerts

ASH Publications

American Society of Hematology

Safety and Anti-Tumor Activity Study of Loncastuximab Tesirine and Ibrutinib in Diffuse Large B-Cell or Mantle Cell Lymphoma

Safety and Anti-Tumor Activity Study of Loncastuximab Tesirine and Durvalumab in Diffuse Large B-Cell, Mantle Cell, or Follicular Lymphoma

Results from Enestgoal: A Phase 2 Study of Treatment-Free Remission (TFR) in Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Switched from Imatinib to Nilotinib

ENESTgoal Treatment-Free Remission Study: Updated Preliminary Results and Digital Polymerase Chain Reaction Analysis in Patients with Chronic Myeloid Leukemia in Chronic Phase Who Switched from Imatinib to Nilotinib

ENESTnext Final Results: Deep Molecular Response (MR) with Nilotinib (NIL) in Patients (pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP)

Rapid Achievement of MR 4.5 after Switching from Imatinib (IM) to Nilotinib (NIL) in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Preliminary Results from ENESTgoal

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only